BAM
RXRX icon

Belpointe Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Belpointe Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-244
Closed -$1.88K – 3835
2022
Q4 		$1.88K Buy
+244
New +$2.39K ﹤0.01% 3281

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Belpointe Asset Management's RXRX Position: Q1 2023 in Review

Belpointe Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2023, closing a stake of 244 shares — an estimated $1.88K sold.

Belpointe Asset Management first reported a position in RXRX in Q4 2022 and held it in 1 quarter. The position peaked at $1.88K in Q4 2022. 158 funds tracked by Wall St. Rank hold RXRX as of Q1 2023.

  • Belpointe Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 244 Recursion Pharmaceuticals shares in Q1 2023, an estimated $1.88K.
  • Belpointe Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Recursion Pharmaceuticals position peaked at $1.88K in Q4 2022.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.